Form 4: ClearPoint Neuro Director Settles Stock Units

Linda M. Liau, a Director at ClearPoint Neuro, Inc., has settled 12,417 restricted stock units, receiving an equivalent number of common shares.

Summary

• Linda M. Liau, a Director of ClearPoint Neuro, Inc., has completed a transaction involving restricted stock units (RSUs).
• On May 19, 2026, 12,417 RSUs vested and were settled, resulting in the receipt of 12,417 shares of common stock.
• These RSUs were originally granted on May 22, 2025, with a vesting schedule tied to the first anniversary of the grant date or the day before the company's 2026 annual meeting, whichever came first.
• Following this transaction, Ms. Liau beneficially owns 64,801 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a routine settlement of equity compensation rather than a significant strategic or financial event.

Positives

• Director Linda M. Liau received vested shares, indicating the fulfillment of a compensation award.
• The settlement of RSUs demonstrates the company's ability to meet its equity-based compensation obligations.

Future Outlook

No specific forward-looking statements or guidance were provided in this filing.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions, providing transparency into executive and director compensation and ownership changes within the medical technology sector.

Stakeholder Impact

• Shareholders: Increased transparency regarding director compensation and share ownership.

Key Dates

Keywords

ClearPoint Neuro, CLPT, Form 4, Insider Trading, Restricted Stock Units, Stock Settlement, Director Compensation, Beneficial Ownership